This study investigated the use of radiogenomics to predict p53 mutations and PD-L1 expression in pancreatic ductal adenocarcinoma (PDAC) patients. 107 PDAC patients were retrospectively analyzed. Immunohistochemistry was used to assess p53 and PD-L1 status. Imaging features (IFs) were extracted from CT scans to create predictive models. The area under the curve (AUC) for p53 and PD-L1 prediction models was 0.795 and 0.683, respectively. Radiogenomics-predicted p53 mutations were significantly associated with poor prognosis (P=0.015). This suggests that radiogenomics may aid in the development of precision medicine for PDAC.
